Sign in →

Test Code LDPU Limited Drug Profile, 3 Drug Classes, Immunoassay, Random, Urine


Ordering Guidance


The test does not screen for drug classes other than those listed in Testing Algorithm.



Specimen Required


Only orderable as part of profile. For more information see CSMHU / Controlled Substance Monitoring Hybrid Drug Panel, 20 Drug Classes, High-Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine.

 

Supplies: Urine Tubes, 10 mL (T068)

Collection Container/Tube: Plastic urine container

Submission Container/Tube: Plastic, 10 mL tube

Specimen Volume: 5 mL

Collection Instructions:

1. Collect a random urine specimen.

2. Submit 5 mL in 10 plastic tube.

3. No preservative


Secondary ID

615289

Useful For

Detecting drug use involving barbiturates, cocaine, and carboxy-tetrahydrocannabinol

 

This test is not intended for use in employment-related testing.

Testing Algorithm

Testing begins with screening tests for drugs of abuse including barbiturates, cocaine, and tetrahydrocannabinol.

 

Positive results can be confirmed and quantitated by definitive methods, gas chromatography mass spectrometry for barbiturates, cocaine and metabolites and liquid chromatography tandem mass spectrometry for tetrahydrocannabinol metabolites, at an additional charge.

Method Name

Only orderable as part of profile. For more information see CSMHU / Controlled Substance Monitoring Hybrid Drug Panel, 20 Drug Classes, High-Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine.

 

Immunoassay

Reporting Name

Limited Drug Panel, 3, IA, U

Specimen Type

Urine

Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Urine Refrigerated (preferred) 14 days
  Frozen  14 days
  Ambient  72 hours

Reject Due To

 All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Clinical Information

This test uses the simple screening technique that involves immunoassay testing for drugs by class. All positive immunoassay screening results can be confirmed by gas chromatography mass spectrometry or liquid chromatography tandem mass spectrometry and quantitated if applicable.

 

This assay was designed to test for the following:

-Barbiturates

-Cocaine

-Carboxy-tetrahydrocannabinol

Reference Values

Only orderable as part of profile. For more information see CSMHU / Controlled Substance Monitoring Hybrid Drug Panel, 20 Drug Classes, High-Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine.

 

Negative

Screening cutoff concentrations:

Barbiturates: 200 ng/mL

Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL

Tetrahydrocannabinol carboxylic acid: 50 ng/mL

 

This report is intended for use in clinical monitoring or management of patients. It is not intended for use in employment-related testing.

Interpretation

For information about drug testing, including estimated detection times, see Drug Class Testing on MayoClinicLabs.com.

Cautions

No significant cautionary statements

Clinical Reference

1. Physicians' Desk Reference. 60th ed. Medical Economics Company; 2006

2. Bruntman LL Lazo JS, Parker KL, eds. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill Book Company; 2006

3. Langman LJ, Bechtel LK, Holstege CP. Clinical toxicology. In: Rifai N, Chiu RWK, Young I, Burnham CAD, Wittwer CT, eds. Tietz Textbook of Laboratory Medicine. 7th ed. Elsevier; 2023:chap 43

4. Jannetto PJ, Bratanow NC, Clark WA, et al. Executive summary: American Association of Clinical Chemistry Laboratory Medicine Practice Guideline-using clinical laboratory tests to monitor drug therapy in pain management patients. J Appl Lab Med. 2018;2(4):489-526

Method Description

The barbiturate, cocaine metabolite, and tetrahydrocannabinol metabolite assays are based on the kinetic interaction of microparticles in a solution as measured by changes in light transmission. In the absence of sample drug, soluble drug conjugates bind to antibody-bound microparticles, causing the formation of particle aggregates. As the aggregation reaction proceeds in the absence of sample drug, the absorbance increases. When a urine sample contains the drug in question, this drug competes with the drug derivative conjugate for microparticle-bound antibody. Antibody bound to sample drug is no longer available to promote particle aggregation, and subsequent particle lattice formation is inhibited. The presence of sample drug diminishes the increasing absorbance in proportion to the concentration of drug in the sample. Sample drug content is determined relative to the value obtained for a known cutoff concentration of drug.(Package inserts: BARB. Roche Diagnostics; V 13.0, 09/2021; THC2. Roche Diagnostics; V 13.0, 03/2022; COC2. Roche Diagnostics; V 9.0, 03/2019)

Day(s) Performed

Monday through Saturday

Report Available

Same day/1 to 2 days

Specimen Retention Time

14 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

80307

LOINC Code Information

Test ID Test Order Name Order LOINC Value
LDPU Limited Drug Panel, 3, IA, U 69739-1

 

Result ID Test Result Name Result LOINC Value
615289 Barbiturates 19270-8
615290 Cocaine 19359-9
615291 Tetrahydrocannabinol 19415-9